The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 28, 2017
Filed:
Sep. 14, 2015
The Regents of the University of California, Oakland, CA (US);
Fondazione Istituto Italiano Di Tecnologia, Genoa, IT;
Universita Degli Studi Di Parma, Parma, IT;
Universita Degli Studi Di Urbino “carlo Bo”, Urbino, IT;
Daniele Piomelli, Irvine, CA (US);
Tiziano Bandiera, Gambolo, IT;
Fabio Bertozzi, Genoa, IT;
Andrea Nuzzi, Davoli, IT;
Annalisa Fiasella, Pisa, IT;
Stefano Ponzano, Florence, IT;
Chiara Pagliuca, Arezzo, IT;
Angelo Mario Reggiani, Recco, IT;
Marco Mor, Ghedi, IT;
Giorgio Tarzia, Petriano, IT;
The Regents of the University of California, Oakland, CA (US);
Fondazione Istituto Italiano di Technologia, Genova, IT;
Universita Degli Studi di Urbino “Carlo Bo”, Urbino, IT;
Universita Degli Studi di Parma, Parma, IT;
Abstract
Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.